Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Oncology InstituteTOIIW 62 12-1 Month Momentum % is N/A% as of Jul. 24, 2026. GuruFocus rates TOIIW with a GF Score™ of 62/100. The stock has 5 warning signs investors should review. Among 661 Healthcare Providers & Services companies, The Oncology Institute ranks better than 85.93% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-07-24), The Oncology Institute's 12-1 Month Momentum % is N/A%.
The industry rank for The Oncology Institute's 12-1 Month Momentum % or its related term are showing as below:
TOIIW's 12-1 Month Momentum % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: -12.21 * Ranked among companies with meaningful 12-1 Month Momentum % only.
The Oncology Institute (NAS:TOIIW) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
The Oncology Institute 12-1 Month Momentum % Related Terms
TOIIW vs CYH, SRTA, CCRN: 12-1 Month Momentum % Comparison
For the Medical Care Facilities subindustry, The Oncology Institute's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Oncology Institute 12-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where The Oncology Institute's 12-1 Month Momentum % falls into.
The Oncology Institute (NAS:TOIIW) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute (TOIIW) has a 12-1 Month Momentum % of N/A% as of Jul. 24, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on The Oncology Institute and its competitors. According to the industry distribution chart, The Oncology Institute ranks #93 out of 661 companies in the Healthcare Providers & Services industry, placing it in the top 14.1%.
Is The Oncology Institute's 12-1 Month Momentum % too high?
The Oncology Institute's current 12-1 Month Momentum % is N/A%. Based on the distribution chart, The Oncology Institute ranks #93 out of 661 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, The Oncology Institute has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's 12-1 Month Momentum % compare to CYH and SRTA?
According to the Healthcare Providers & Services industry distribution chart, The Oncology Institute ranks #93 out of 661 companies for 12-1 Month Momentum %. This places The Oncology Institute in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Healthcare Providers & Services company?
A good 12-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on The Oncology Institute and its competitors. The Oncology Institute's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
The Oncology Institute (TOIIW) has a current 12-1 Month Momentum % of N/A%. The current 12-1 Month Momentum % is N/A%. The Oncology Institute's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For The Oncology Institute (TOIIW), the current 12-1 Month Momentum % is N/A% as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
62GF Score
Get the complete analysis for TOIIW
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOIIW has been successfully added to your 
